Time course of changes in striatal dopamine transporters and D2 receptors with specific iodinated markers in a rat model of Parkinson's disease

Synapse

Volumn 31, Issue 2, 1999, Pages 134-139

  Chalon, Sylvie ^a   Emond, Patrick ^a   Bodard, Sylvie ^a   Vilar, Marie Paule ^a   Thiercelin, Cynthia ^a   Besnard, Jean Claude ^a   Guilloteau, Denis ^a  

^a INSERM   (France)

Author keywords

6 hydroxydopamine; Dopamine; SPET; Tropane derivative

Indexed keywords

6 HYDROXYDOPA; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; IODOBENZENE; NORTROPANE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINE UPTAKE; MALE; NERVE CELL LESION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRESYNAPTIC NERVE; PRIORITY JOURNAL; RAT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; BENZAMIDES; CARRIER PROTEINS; CORPUS STRIATUM; DOPAMINE; DOPAMINE ANTAGONISTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; IODINE RADIOISOTOPES; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; NORTROPANES; PARKINSON DISEASE; PYRROLIDINES; RADIOPHARMACEUTICALS; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D2; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0032917977     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2396(199902)31:2<134::AID-SYN6>3.0.CO;2-V     Document Type: Article

References (23)

1. Abi-Dargham A, Laruelle M, Seibyl J, Rattner Z, Baldwin RM, Zoghbi SS, Zea-Ponce Y, Bremner JD, Hyde TM, Charney DS, Hoffer PB, Innis RB. 1994. SPECT measurement of benzodiazepine receptors in human brain with iodine-123-iomazenil: Kinetic and equilibrium paradigms. J Nucl Med 35:228-238.
2. Agid Y, Javoy F, Glowinski J. 1973. Hyperactivity of remaining dopaminergic neurons after partial destruction of the nigro-striatal dopaminergic system in the rat. Nature 245:150-151.
3. Asenbaum S, Brücke T, Pirker W, Podreka I, Angelberger P, Wenger S, Wöber C, Müller C, Deecke L. 1997. Imaging of dopamine transporters with iodine-123-β-CIT and SPECT in Parkinson's disease. J Nucl Med 38:1-6.
4. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. 1973. Brain dopamine and the syndromes of Parkinson and Huntington: Clinical, morphological, and neurochemical correlations. J Neurol Sci 20:415-455.
5. 125I]RTI-55 to dopamine and serotonin transporters in rat brain. Synapse 12:27-36.
6. Brücke T, Podreka I, Angelberger P, Wenger S, Topitz A, Küfferle B, Müller C, Deecke L. 1991. Dopamine D2 receptor imaging with SPECT: Studies in different neuropsychiatric disorders. J Cereb Blood Flow Metab 11:220-228.
7. 2 receptor and preproenkephalin mRNA after nigrostriatal dopaminergic denervation in the rat. Mol Brain Res 19:318-322.
8. Emond P, Garreau L, Chalon S, Boazi M, Caillet M, Bricard J, Frangin Y, Mauclaire L, Besnard J-C, Guilloteau D. 1997. Synthesis and ligand binding of nortropane derivatives: N-substituted-2β-carbomethoxy-3β-(4′-iodophenyl) nortropane and N-(3-iodoprop-2E-enyl)-2β-carbomethoxy-3β-(3′,4′- disubstitutedphenyl) nortropane. New affinity and selective compounds for the dopamine transporter. J Med Chem 40:1366-1372.
9. 2 dopamine receptors and dopamine uptake sites in the 6-hydroxydopamine lesioned rat - An autoradiographic study. Brain Res 640:185-194.
10. Guilloteau D, Emond P, Baulieu J-L, Garreau L, Frangin Y, Pourcelot L, Mauclaire L, Besnard J-C, Chalon S. 1998. Exploration of the dopamine transporter: In vitro and in vivo characterization of a high affinity and high specificity iodinated tropane derivative (E)-N-(3-iodoprop-2-enyl)-2β-(4′-methylphenyl) nortropane or PE2I. Nucl Med Biol 25:331-337.
11. Innis RB, Seibyl JP, Scanley BE, Laruelle M, Abi-Dargham A, Wallace E, Baldwin RM, Zea-Ponce Y, Zoghbi S, Wang S, Gao Y, Neumeyer JL, Charney DS, Hoffer PB, Marek KL. 1993. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson's disease. Proc Natl Acad Sci USA 90:11965-11969.
12. Jeon BS, Jackson-Lewis V, Burke RE. 1995. 6-Hydroxydopamine lesion of the rat substancia nigra: Time course and morphology of cell death. Neurodegeneration 4:131-137.
13. Kuikka JT, Baulieu J-L, Hiltunen J, Halldin C, Bergström KA, Farde L, Emond P, Chalon S, Yu M, Nikula T, Leitinen T, Karhu J, Tupala E, Hallikainen T, Kolehmainen V, Mauclaire L, Mazière B, Tiihonen J, Guilloteau D. 1998. Pharmacokinetics and dosimetry of iodine-123 labelled PE2I in humans, a radioligand for dopamine transporter imaging. Eur J Nucl Med 25:531-534.
14. 123I]IBZM: A potential dopamine D2 receptor imaging agent. J Lab Comp Radiopharm XXVII:691-700.
15. Kung MP, Essman WD, Frederick D, Meegala S, Goodman M, Mu M, Lueki I, Kung HF. 1995. IPT: A novel iodinated ligand for the CNS dopamine transporter. Synapse 20:316-324.
16. Laulumaa V, Kuikka JT, Soininen H, Bergström K, Länsimies E, Riekkinen P. 1993. Imaging of D2 dopamine receptors of patients with Parkinson's disease using single photon emission computed tomography and iodobenzamide I-123. Arch Neurol 50:509-512.
17. Lee T, Seeman P, Rajput A, Farley IJ, Hornykiewicz O. 1978. Receptor basis for dopaminergic supersensitivity in Parkinson's disease. Nature 273:59-61.
18. Marshall JF, Navarette R, and Joyce JN. 1989. Decreased striatal D1 binding density following mesotelencephalic 6-hydroxydopamine injections: An autoradiographic analysis. Brain Res 493:247-257.
19. Nadeau SE, Couch MW, Devane CL, Shukla SS. 1995. Regional analysis of D2 dopamine receptors in Parkinson's disease using SPECT and iodine-123-iodobenzamide. J Nucl Med 36:384-393.
20. Paxinos G, Watson C. 1986. The rat brain in stereotaxic coordinates. New York: Academic Press.
21. Schwarting RKW, Huston JP. 1996. Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae. Prog Neurobiol 49:215-266.
22. 123I]β-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 38:589-598.
23. Tatsch K, Schwarz J, Mozley PD, Linke R, Pogarell O, Oertel WH, Fieber RS, Hahn K, Kung HF. 1997. Relationship between clinical features of Parkinson's disease and presynaptic dopamine transporter binding assessed with [123I]IPT and single-photon emission tomography. Eur J Nucl Med 24:415-421.